Medical Properties Trust, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MPT research report →
Range $3.8 – $3.8
Price Chart
About the company
Medical Properties Trust, Inc. functions as a self-managed real estate investment trust (REIT). The company specializes in the financing, acquisition, and construction of healthcare properties, all structured under net-lease agreements.
- CEO
- Edward K. Aldag Jr.
- IPO
- 2005
- Employees
- 121
- HQ
- Birmingham, AL, US
AI snapshot
Six angles, distilled from the data.
The stock remains in a deep recovery phase, still below its 200-day average of 4.84 and 50-day average of 4.19. It is trading closer to the 52-week low of 3.36 than the 52-week high of 6.09, which keeps the long-term trend cautious despite a recent stabilization.
Street sentiment is mixed but leans cautious: consensus is Hold, and the average target has compressed to 3.80. Recent action has been uneven, with Wells Fargo cutting its target to 3.80 from 5.00 while earlier upgrades and higher targets still frame a wide valuation debate.
The earnings setup is uneven but improving at the margin. MPT has beaten in 2 of the last 7 quarters, and next-year EPS is modeled at 0.05 versus TTM EPS of -0.05. Shareholders should watch whether the next report extends the recent pattern of small beats and steadier operating trends.
Activity skews constructive, led by one open-market buy from the Senior VP, Controller & CAO. Most of the larger filings are F-code in-kind or award-related transactions tied to compensation mechanics, so the only clear discretionary signal is modest net buying rather than broad insider selling.
Operating performance is still pressured, but cash generation remains a support. Gross margin is 95.9% and operating margin is 57.36%, while net margin is -2.73% and ROE is slightly negative at -0.62%. Revenue grew 1.9% year over year, and free cash flow reached 452.9 million.
MPT screens as a high-yield healthcare REIT with stronger cash flow than its earnings profile suggests, but leverage remains heavy at 9.83 billion of debt against 540.9 million of cash. At 6.05x earnings, the valuation is modest versus the sector, but the balance sheet keeps the setup selective.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $2.14B
- P/E
- -68.00
- Fwd P/E
- 87.47
- PEG
- -0.12
- P/S
- 2.09
- P/B
- 0.47
- EV/EBITDA
- 10.88
- Div Yield
- 10.08%
- Gross Margin
- 82.48%
- Op Margin
- 56.61%
- Net Margin
- -2.96%
- ROE
- -0.66%
- ROIC
- 3.75%
Latest fiscal year · YoY change
- Revenue
- $972.02M-2.4%
- Gross Profit
- $935.61M-3.4%
- Op Income
- $539.77M
- Net Income
- $-277,049,000+88.5%
- EPS
- $-0.46+88.6%
- OCF Growth
- -6.0%
- FCF Growth
- -6.0%
- 52W High
- $6.47
- 52W Low
- $3.36
- 50D MA
- $4.16
- 200D MA
- $4.83
- Beta
- 1.44
- RSI (14)
- 39
- Avg Volume
- 8.01M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Medical Properties Trust said Q2 normalized FFO was in line with expectations, while a large refinancing pushed out near-term maturities and management highlighted improving asset values and continued rent recovery.· August 10, 2026
- Normalized FFO was $0.15 per share, in line with expectations, versus $0.14 last quarter.
- Management announced a two-step refinancing that will eliminate 2026 and 2027 maturities and leave only about $600 million due in June 2028.
- Post-acute performance was strongest, with EBITDARM up more than $70 million year over year; behavioral health remained pressured, especially in the UK and US.
- HSA remained the main operational concern because cash collections are still lagging even though coverage is around 2.0x; management said collections are still only in the eighties.
- Asset sales are starting to validate values above book, with one imminent sale expected to generate about $172 million in after-debt cash proceeds.
Medical Properties Trust reported normalized FFO of $0.15 per share for Q2 2026, versus $0.14 last quarter. General acute operators reported aggregate EBITDARM coverage of 2.8x, post-acute coverage was 2.4x, and behavioral coverage was 1.4x. Management said post-acute EBITDARM increased more than $70 million year over year, led by Median up 24% and Ernest Health up 13%. The company impaired approximately $17 million in working capital loans, primarily tied to two Steward replacement tenants in the Midwest. Forward guidance and outlook: management said the refinancing extends $2.4 billion of debt maturities to 2032 and, after step 2, MPT will have no debt maturing in 2026 or 2027 and only about $600 million due in June 2028. Management expects about $1.1 billion of liquidity from recent and near-term asset sales and said it remains on track to reach over $1 billion of annualized cash rent by year-end. HSA is paying 75% of contractual rent and rises to 100% in mid-September; NOR is paying 50% and rises to 100% in mid-December.
Ed Aldag framed the quarter around balance-sheet repair and asset-value validation. He emphasized that the refinancing removes near-term maturity pressure and gives the company room to pursue a more balanced capital allocation strategy while continuing to reduce leverage. Operationally, he pointed to robust demand in rehabilitation services, stronger post-acute trends, and continued confidence in Switzerland, while acknowledging behavioral health and UK funding pressures.
Kevin Hanna said Q2 normalized FFO of $0.15 per share was in line with expectations, helped by rent step-ups at HSA and NOR. He also noted higher year-over-year G&A driven by stock compensation tied to cash-settled awards and depreciation from the headquarters building placed in service in Q1, plus about $17 million of working capital loan impairments tied mainly to the two Steward replacement tenants. Steve Hamner detailed the financing: $2.4 billion of secured notes at a 9.25% coupon and 5.5-year term, repayment/exchange of 2026 and 2027 maturities, roughly $123 million of gross debt reduction from exchanging longer-dated notes, and covenant headroom improving from around 1.55x-1.60x to as much as 200% after step 1 and up to 300% after step 2.
Analysts focused on how step 2 would be funded, whether the balance of the 2027 notes would be handled via a new credit line, and how much additional secured debt capacity remained. Management said step 2 would not rely only on the credit line and could use asset sales, existing liquidity, and additional secured debt opportunities; it also said the secured-debt ratio would move from about 25% toward the 40% area, with asset sales creating more headroom. Questions also centered on HSA cash collections and Florida supplemental funding; Aldag said collections are still in the eighties, Florida has already sent about half of the DPP money, and the rest could come within a week, enabling repayment of working capital advances. On NOR, management confirmed rent has started and said Prospect is doing well.
The refinancing sharply reduces near-term maturity risk and leaves management with more flexibility to delever on its own timetable. Management also described multiple asset sales at prices above book value, including one closing that should produce about $172 million after debt and additional deals that could add $200 million to $400 million more.
Behavioral health remains pressured, especially in the UK and US, and Priory is still dealing with NHS referral pattern changes and budget constraints. HSA is still a drag because cash collections are lagging despite decent coverage, and management said improvement has been slower than hoped, with liquidity dependent on delayed supplemental payments and operational fixes.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 82.0%
- Shares Outstanding
- 598.10M
- Float Shares
- 490.65M
Buy/sell ratio 0.17. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 152 ETFs
Biggest fund positions in MPT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 20, 26 | Hanna James Kevin | buy | 2,300 |
| Jul 8, 26 | Portal Larry H | other | 4,048 |
| Jul 8, 26 | LAMBERT CHARLES R | other | 2,347 |
| Jul 8, 26 | Aldag Edward K JR | other | 109,433 |
| Jul 8, 26 | HAMNER R STEVEN | other | 48,548 |
| Jul 8, 26 | Hanna James Kevin | other | 3,295 |
| Jul 8, 26 | Williams Rosa Handley | other | 1,938 |
| Apr 8, 26 | Aldag Edward K JR | other | 109,433 |
| Apr 8, 26 | HAMNER R STEVEN | other | 48,548 |
| Apr 8, 26 | Portal Larry H | other | 4,048 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MPT coverage
Recent articles, reports, and earnings notes.

Medical Properties Trust (MPW): Rent Recovery vs. Leverage Risk
Medical Properties Trust shows a credible stabilization story as rent ramps and restructurings improve, but heavy leverage and tenant risk keep the stock in Hold territory.

Medical Properties Trust, Inc. (MPT) falls on deep earnings
Medical Properties Trust, Inc. (MPT) beat EPS and revenue, yet shares fell as investors looked past the headline to debt, rent collection, and tenant recovery. This deep-dive examines coverage ratios, refinancing progress, normalized FFO, and the path to more durable cash flow.

Medical Properties Trust, Inc. (MPT) falls on earnings beats
Medical Properties Trust, Inc. (MPT) falls 11.4% after reporting earnings beats, as investors react to the latest results and outlook.
Want a deeper read on MPT?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Medical Properties Trust: A $680 Million Reality Check
seekingalpha.com · Sep 23
What next for Medical Properties Trust stock amid asset sales?
invezz.com · Sep 17
MPT Completes the Sale of Two Hospitals for $371 Million in Cash
businesswire.com · Sep 16
Medical Properties Trust: Recent Debt Exchange Doesn't Fix Fundamental Issues
seekingalpha.com · Sep 15
2 REITs, $0 I'd Invest: Here's My Case Against The Crowd Favorites
seekingalpha.com · Sep 14
Medical Properties Trust: Refinancing Hit Flips Risk Reward, Upgrade To 'Cautious Buy'
seekingalpha.com · Sep 14
Net Lease REITs: Diversification Or Diworsification?
seekingalpha.com · Sep 13
Unlocking Deep Asset Value In Medical Properties Trust
seekingalpha.com · Aug 19
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed September 27, 2026 · Live quote · Not investment advice